5 episodes
A Chat with Anat ApotheCom
-
- Science
'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused care. This podcast series is sponsored and organised by Bayer and produced by ApotheCom. This is not intended for UK audiences.
-
Exploring the research gap of patient perspectives
My guest for this episode is Professor Richard Gale, Professor of Ophthalmology at Hull York Medical School, University of York, UK, and Honorary Consultant Medical Ophthalmologist at the National Health Service’s York Teaching Hospital.
In this episode, Richard and I will chat about how patients’ emotions, experiences, and perceptions related to anti-vascular endothelial growth factor (anti-VEGF) treatment can influence their treatment adherence and persistence. Despite this, the patient’s perspective is often not considered during the clinical management of neovascular age-related macular degeneration. To tackle this issue, Richard gives us some of his top tips to try in our busy clinics.
We discuss a systematic literature review article recently published in Acta Ophthalmologica, which was authored by a group of international experts including Richard and myself. Find out more here: https://doi.org/10.1111/aos.15201
If you enjoyed this episode, go back and listen to our first episode with Richard, where we chat about how to further motivate our patients to be adherent, or try some of the past episodes to hear other retinal experts delve into ways to engage and empower our patients, and explore a history of patient expectations in nAMD through the 21st century.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/
Further information on other studies mentioned in this episode:
ANCHOR study: https://doi.org/10.1016/j.ophtha.2008.10.018
MARINA study: https://doi.org/10.1016/j.ophtha.2006.10.045
Prevalence and risk factors for depressive symptoms in patients with nAMD; Australian study: https://doi.org/10.1111/aos.14635
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Professor Richard Gale:
Consultancy, Research Grants: Alimera, Allergan, Bayer, Novartis, Roche -
Evolution of patient expectations in nAMD through the 21st century
My guest for this episode is Professor Paul Mitchell, Emeritus Professor of Ophthalmology at the University of Sydney, Consultant Ophthalmologist at the Western Sydney Local Health District, and Principal of Sydney West Retina Pty Ltd in Australia.
As treatment for neovascular age-related macular degeneration (nAMD) has evolved through the 21st century, so have the expectations of our patients. Paul joins me to chat about how developments in treatment modalities and regimens led to the evolution of patient expectations following diagnosis of nAMD, and what we can expect for our patients in the future.
If you enjoyed this episode, try some of our past episodes to hear other retinal experts delve into ways in which we can engage and empower our patients, how to further motivate our patients to be adherent, and how clinic organization can be used to improve adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/
Further information on studies mentioned in this episode:
Blue Mountains Eye study (https://doi.org/10.1016/S0161-6420(95)30846-9)
MARINA study (https://doi.org/10.1056/NEJMoa054481)
ANCHOR study (https://doi.org/10.1016/j.ophtha.2008.10.018)
LUCAS study (https://doi.org/10.1016/j.ophtha.2014.07.041)
ALTAIR study (https://doi.org/10.1007/s12325-020-01236-x)
ARIES study (https://doi.org/10.1097/IAE.0000000000003128)
HOME study (https://doi.org/10.1016/j.cct.2014.02.003)
Algorithm for suspending anti-VEGF treatment in cases of futility (https://doi.org/10.1097/IAE.0000000000002713)
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Professor Paul Mitchell
Consultancy: Allergan, Bayer, and Novartis -
Ways to engage with patients to enable realistic expectation-setting
My guest is Dr. Jane Barratt, Secretary General of the International Federation on Ageing. In this episode, Jane and I discuss ways in which we can improve our communication with our patients to enable realistic expectation-setting. We also speak about how we can meaningfully engage with, and empower, our patients to support them in managing their nAMD.
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane -
How to improve your clinic organisation to ensure a better patient experience, and optimise adherence to treatment
Today my guest is Mr James Talks, Consultant Ophthalmologist at the Newcastle Eye Centre in Newcastle, UK. He joins me to discuss how clinic organisation can impact adherence and persistence and what aspects we can modify to ensure a better patient experience and optimise adherence to treatment.
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Mr James Talks
Consultancy, Research grants: Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche -
How to motivate my patient to be adherent
My first guest is Professor Richard Gale, Consultant Medical Ophthalmologist, and the Clinical Director at the York Teaching Hospital NHS Foundation Trust, UK. In this episode, we discuss the latest publications and strategies that are employed to support patients in continuing to attend appointments and receive treatment. I have included below the links to the publications that we discuss during this podcast.
Okada M, et al. Ophthalmology. 2021;128(2):234-47
Okada M, et al. JAMA Ophthalmol. 2021;139(7):769-76
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Professor Richard Gale:
Consultancy, Research Grants: Alimera, Allergan, Bayer, Novartis, Roche
Top Podcasts In Science